Related Experiment Videos
A new procedure for detecting brain-specific proteins in cerebrospinal fluid
P Davidsson1, R Ekman, K Blennow
1Department of Clinical Neuroscience, Göteborg University, Mölndal Hospital, Sweden.
Journal of Neural Transmission (Vienna, Austria : 1996)
|January 1, 1997
Summary
Researchers identified reduced levels of brain-specific transthyretin (TTR) in cerebrospinal fluid (CSF) of early-onset Alzheimer's disease (AD) patients. This finding suggests TTR may serve as a potential biomarker for neurodegenerative disorders like AD.
Area of Science:
- Neuroscience
- Biochemistry
- Proteomics
Background:
- Degenerative brain disorders, such as Alzheimer's disease (AD), are characterized by neuronal and synaptic dysfunction.
- Identifying reliable biochemical markers in cerebrospinal fluid (CSF) is crucial for understanding disease pathology and progression.
- Transthyretin (TTR) is a brain-specific protein with potential roles in neurodegenerative processes.
Purpose of the Study:
- To develop and apply a novel procedure for analyzing central nervous system (CNS) specific proteins in human CSF.
- To identify potential biochemical markers for neuronal and synaptic function and pathology in degenerative brain disorders.
- To investigate the levels of specific CSF proteins, particularly transthyretin (TTR), in Alzheimer's disease (AD) patients.
Main Methods:
- A multi-step purification process involving affinity chromatography and micro-reversed-phase high-performance liquid chromatography (mR-HPLC).
- Proteins were identified using Western blotting and mass spectrometric analysis.
- Quantification of TTR in CSF and serum samples from AD patients (early and late onset), vascular dementia patients, and healthy controls using nephelometry.
Main Results:
- Four major CSF proteins identified: beta 2-microglobulin, cystatin C, transthyretin (TTR), and asialotransferrin.
- A significant reduction in brain-specific (barrier-independent) TTR was observed in the cerebrospinal fluid (CSF) of early-onset Alzheimer's disease (EAD) patients compared to controls.
- TTR has been found in senile plaques and binds to beta/A4 protein, suggesting its potential involvement in AD amyloid pathology.
Conclusions:
- The novel analytical procedure effectively isolates and identifies CNS-specific proteins in human CSF.
- Reduced levels of brain-specific TTR in CSF may serve as a potential biomarker for early-onset Alzheimer's disease.
- The observed reduction in TTR could be attributed to its absorption onto amyloid deposits in senile plaques characteristic of AD.